Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-03-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1056/NEJMOA054013PMID 16554528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

  2006cited by this paper
• Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M400396-JLR200

  2005cited by this paper
• Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

  2004cited by this paper
• NARC-1/PCSK9 and Its Natural Mutants

  2004cited by this paper
• Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver*

  2004cited by this paper
• Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

  2004cited by this paper
• ZYMOGEN CLEAVAGE AND EFFECTS ON THE LOW DENSITY LIPOPROTEIN (LDL) RECEPTOR AND LDL CHOLESTEROL

  2004cited by this paper
• Starting earlier to prevent heart disease.

  2003cited by this paper
• The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation

  2003cited by this paper
• Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.

  2003cited by this paper
• Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.

  2000cited by this paper
• Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study.

  1999cited by this paper
• Determinants of atherosclerosis in the young

  1998cited by this paper
• Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.

  1998cited by this paper
• Identification and molecular analysis of two apoB gene mutations causing low plasma cholesterol levels.

  1995cited by this paper
• Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study.

  1993cited by this paper
• Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.

  1991cited by this paper
• High‐resolution B‐Mode Ultrasound Scanning Methods in the Atherosclerosis Risk in Communities Study (ARIC)

  1991cited by this paper
• The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators

  1989cited by this paper
• The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

  1989cited by this paper
• Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

  1986cited by this paper
• Coronary artery disease in combat casualties in Vietnam.

  1971cited by this paper
• Coronary disease among United States soldiers killed in action in Korea; preliminary report.

  1953cited by this paper

• Lipid metabolic alterations in cancer: common pathophysiology with cardiovascular disease.

  2026cites this paper
• RNA interference therapeutics for disease-associated proteins: from molecular design to clinical translation

  2026cites this paper
• Effect heterogeneity reveals complex pleiotropic effects of rare coding variants

  2026cites this paper
• The impact of cumulative low-density lipoprotein cholesterol on prognosis in coronary heart disease patients: A retrospective study based on time-weighted cumulative exposure.

  2026cites this paper
• Expert consensus on the management of patients with cerebrovascular diseases and lipid metabolism disorders: focus on primary and secondary prevention

  2026cites this paper
• The evolving therapeutic landscape of PCSK9 inhibition.

  2026cites this paper
• Cholesterol: an ancient ally or modern menace?

  2026cites this paper
• Impact of loss-of-function variations of PCSK9 on LDLR interaction and dynamics: Implications for heart function.

  2026cites this paper
• Multi-omics signatures of chronic inflammation across immune-related disease states.

  2026cites this paper
• Inherited risk of coronary artery disease: redefining care with imaging and genetics.

  2026cites this paper
• Cardiovascular Science, Medicine, and Society: The Brave New World: The ACC Braunwald Lecture 2025.

  2026cites this paper
• Modifier gene identification reveals therapeutic pathways for adult and childhood dementias

  2026cites this paper
• The polygenic, omnigenic and stratagenic models of complex disease risk

  2026cites this paper
• Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress

  2026cites this paper
• Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort

  2026cites this paper
• Recent insights into the pathophysiology and implications for surgery in atherosclerosis

  2025cites this paper
• Multiscale genetics-to-structure analysis identifies calcium homeostasis as core mechanism in psychiatric disorders

  2025cites this paper
• Advancing Risk Gene Discovery Across the Allele Frequency Spectrum

  2025cites this paper
• Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates.

  2025cites this paper
• Mapping the plasma metabolome to human health and disease in 274,241 adults

  2025cites this paper
• [Forty years of advances in cardiology].

  2025cites this paper
• Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia

  2025cites this paper
• Lipid-lowering drug targets influence inflammatory bowel disease through gut microbiota and inflammatory cytokines

  2025cites this paper
• No association between LDL cholesterol levels and cellular membrane integrity assessed with phase angle: Insights from the MALIPID study.

  2025cites this paper
• PCSK9 Regulation of Lipid Metabolism in the Nervous System: Implications for Schwann Cell Function and Peripheral Neuropathy

  2025cites this paper
• Advancements in lipid-lowering therapy: the role of proprotein convertase subtilisin/kexin type 9 inhibitors and beyond in cardiovascular risk reduction.

  2025cites this paper
• Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk

  2025cites this paper
• Comprehensive gene heritability estimation reveals the genetic architecture of rare coding variants underlying complex traits

  2025cites this paper
• Antibody-Based Therapeutics for Hypercholesterolemia

  2025cites this paper
• Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies

  2025cites this paper
• Using Large Genomic Biobanks to Generate Insights into Genetic Kidney Disease.

  2025cites this paper
• Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial

  2025cites this paper
• Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins

  2025cites this paper
• Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China

  2025cites this paper
• The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.

  2025cites this paper
• RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study.

  2025cites this paper
• Humoral determinants of checkpoint immunotherapy

  2025cites this paper
• Impact of PCSK9 gene polymorphism on atorvastatin efficacy in Iraqi hyperlipidemic patients

  2025cites this paper
• Clinical Effect of Evolocumab treatment in coronary artery bypass surgery

  2025cites this paper
• Landscape of rare‐allele variants in cultivated and wild soybean genomes

  2025cites this paper
• Rare biochemical & genetic conditions: clues for broader mechanistic insights

  2025cites this paper
• Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data

  2025cites this paper
• Prognostic value of lipid parameters among patients with heart failure: A systematic review and meta‐analysis

  2025cites this paper
• Integrating Expression Quantitative Trait Loci and Genome-Wide Association Study Identifies Druggable Genes for Tinnitus.

  2025cites this paper
• Association of Plasma PCSK9 with Hypercholesterolemia in Patients with Nephrotic Syndrome

  2025cites this paper
• Heterozygous Korat cats with LDL receptor mutation are asymptomatic and normolipidemic.

  2025cites this paper
• Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy—A Review

  2025cites this paper
• S-Nitrosylation: Mechanistic Links between Nitric Oxide Signaling and Atherosclerosis

  2025cites this paper
• Ateroesclerosis. Etiopatogenia. Placa estable y placa vulnerable. Rotura de placa. Resumen de las manifestaciones clínicas a nivel sistémico

  2025cites this paper
• Whole genome sequence analysis of low-density lipoprotein cholesterol across 246 K individuals

  2025cites this paper
• Functional gene embeddings improve rare variant polygenic risk scores

  2025cites this paper
• Molecular Docking and Functional Analysis of APOA5 (G185C), PCSK9 (R46L, R93C), LPL (N318S), and LIPA (T16P) Genes Mutations Associated with Coronary Artery Disease

  2025cites this paper
• The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease

  2025cites this paper
• NPC1 as a novel therapeutic target for induction of pyroptosis in cancers

  2025cites this paper
• The influence of vegetarian and omnivorous diet quality on metabolic profiles and cardiovascular risk

  2025cites this paper
• Aaptamine attenuates the action of statin on PCSK9 and LDLR expression as well as LDL-C uptake in human liver cells

  2025cites this paper
• Significant Association Between Glucokinase Regulatory Protein Variants and Genetic and Metabolic Diseases

  2025cites this paper
• Association of matrix metalloproteinase-10 levels and genetic variant rs17860955 with severe vascular complications in patients with type 1 diabetes: prospective cohort.

  2025cites this paper
• Next-generation PCSK9 inhibitors: clinical evidence and future directions for cardiovascular prevention

  2025cites this paper
• PCSK9 in critical illness - it's not all about lipids.

  2025cites this paper
• Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease.

  2025cites this paper
• Pervasive context-dependent effects in the genetic architecture of complex and quantitative traits revealed by a powerful multiparent mapping population in yeast

  2025cites this paper
• Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

  2025cites this paper
• Immune checkpoint inhibitors and myocardial infarction.

  2025cites this paper
• Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table.

  2025cites this paper
• A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels

  2025cites this paper
• Silencing FAF2 mitigates alcohol-induced hepatic steatosis by modulating lipolysis and PCSK9 pathway

  2025cites this paper
• PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling

  2025cites this paper
• Causal modeling of gene effects from regulators to programs to traits: integration of genetic associations and Perturb-seq

  2025cites this paper
• Insights Into Causal Effects of Genetically Proxied Lipids and Lipid‐Modifying Drug Targets on Cardiometabolic Diseases

  2025cites this paper
• Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis

  2025cites this paper
• Enhanced genome editing with a Streptococcus equinus Cas9

  2025cites this paper
• Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

  2025cites this paper
• Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria

  2025cites this paper
• A study into rare GPR146 gene variants in humans and mice.

  2025cites this paper
• Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering

  2025cites this paper
• PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling

  2025cites this paper
• PCSK9 genetic variants, carotid atherosclerosis and vascular remodelling

  2025influential citation
• Illuminating the Protective Role of UPF1 in Myocardial Ischemia/Reperfusion Injury

  2025cites this paper
• Bayesian inference of genetic pleiotropy identifies drug targets and repurposable medicines for human complex diseases

  2025cites this paper
• Research Progress of Cardiovascular Protection Mechanism of PCSK9 Inhibitors

  2025cites this paper
• Can AI reveal the next generation of high-impact bone genomics targets?

  2025cites this paper
• Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk.

  2025cites this paper
• Genetic Determinants of the Familial Hypercholesterolaemia Phenotype

  2025cites this paper
• PCSK9 in Vascular Aging and Age-Related Diseases

  2025cites this paper
• Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial.

  2025cites this paper
• An evaluation of recaticimab for the treatment of hypercholesterolemia

  2025cites this paper
• Cell Modeling and Rescue of a Novel Non-coding Genetic Cause of Glycogen Storage Disease IX

  2025cites this paper
• Bench to all Bedsides in Genomics and Precision Medicine

  2025cites this paper
• PCSK9 and coronary atherosclerosis progression beyond LDL‐cholesterol in coronary artery disease patients

  2025cites this paper
• Causal validation between 179 lipids and hyperparathyroidism: A bidirectional Mendelian randomization combined meta-analysis with mediation factors

  2025cites this paper
• MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9

  2025cites this paper
• Schisandrin C Improves Chronic Stress-Induced Dyslipidemia in Mice by Regulating Pyroptosis and Autophagy Levels

  2025cites this paper
• Cardiovascular risk management beyond statins: review of new therapies available in Italy

  2025cites this paper
• Gene Editing Applications as Future Cardiovascular Therapies.

  2025cites this paper
• Pushing the Limits of LDL Cholesterol: Emerging Paradigms in Cardiovascular Risk Reduction.

  2025cites this paper
• A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II

  2025cites this paper
• Unravelling Osteoporosis: Key Genes and Potential Therapies

  2025cites this paper
• The relationship between serum alkaline phosphatase levels and sepsis: observational and Mendelian randomization studies

  2025cites this paper
• Molecular Therapeutics in Development to Treat Hyperlipoproteinemia

  2025cites this paper